- Home
- NMRA vs RGNX Comparison
NMRA vs RGNX Comparison
Compare NMRA & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | RGNX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.0M | 528.6M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NMRA | RGNX |
|---|---|---|
| Price | $1.45 | $10.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $7.50 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 3.3M | 1.9M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.23 | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $0.72 | $5.46 |
| 52 Week High | $3.65 | $16.19 |
Technical Indicators
Market Signals| Indicator | NMRA | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 71.08 |
| Support Level | $0.83 | $9.51 |
| Resistance Level | $2.08 | $11.00 |
| Average True Range (ATR) | 0.19 | 0.78 |
| MACD | 0.01 | 0.48 |
| Stochastic Oscillator | 63.86 | 80.39 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.